Status and prospect of CAR-T cell therapy for prostate cancer

VernacularTitle:CAR-T疗法在前列腺癌中的治疗现状与应用前景
Author: Jiawen HUANG ¹ ; Chengyu ZOU ; Yida ZHANG
Author Information

1. 南昌大学第一附属医院泌尿外科，南昌　330006
Keywords: Prostatic neoplasms; Carcinoma; Chimeric antigen receptor T-cell; Immunotherapy
From: Chinese Journal of Urology 2022;43(11):877-880
CountryChina
Language:Chinese
Abstract: At present, the treatment of advanced tumors has entered the immune era, and immune checkpoint inhibitors have shown good efficacy in prostate cancer. Cellular immunotherapy such as CAR-T therapy (chimeric antigen receptor T-cell immunotherapy) has shown excellent results in hematological and digestive system malignancies, but its efficacy in urinary system tumors is not yet clear. This review will explain the current status and application prospects of CAR-T in the treatment of prostate cancer, including target selection, predicament, and function enhancement strategies of CAR molecules in prostate cancer, aiming to open up new perspectives for cellular immunotherapy of prostate cancer and ideas.